A股异动 | 中来股份(300393.SZ)拟定增募资不超19.12亿元 控股股东将变更为姜堰道得
格隆汇10月23日丨中来股份(300393.SZ)今日复牌低开低走,现报11.01元,跌8.78%,暂成交4.3亿元,最新总市值85.7亿元。中来股份昨晚披露向特定对象发行股票预案,拟发行数量为2.33亿股,发行价为8.19元/股,募集资金总额19.12亿元,扣除发行费用后将全额用于补充公司流动资金。此次发行对象为泰州姜堰道得新材料股权投资合伙企业(有限合伙)。预计本次发行完成后,此次发行后,姜堰道得控制上市公司的股份比例将由18.70%上升为37.46%,公司控股股东将变更为姜堰道得。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.